The sale Vecoxan marks Elanco’s third product divestment in North America this year
|
The sale of Vecoxan marks Elanco’s third product divestment in North America this year
|
The two are set to work collaboratively on research aimed at improving the overall health of animals
|
The animal health company has sold the U.S. rights for its Capstar product to PetIQ
|
The animal health company has sold the global rights for its Osurnia product to the United Kingdom’s Dechra Pharmaceuticals
|
The animal health company has sold the global rights for its Osurnia product to the U.K.’s Dechra Pharmaceuticals
|
The sale is part of the company’s announced global overhaul, which includes the elimination of 250 jobs in various locations
|
The sale is part of the company’s announced global overhaul, which includes the elimination of 250 jobs in various locations
|
When it comes to joint inflammation, the most astute observations begin at home
|
When it comes to joint inflammation, the most astute observations begin at home
|
The company says the “restructuring” will realize $12m of savings in 2020
|
The company says the “restructuring” will realize $12m of savings in 2020
|
The deal doubles Elanco’s companion animal business, becoming number two in the world
|
The deal doubles Elanco’s companion animal business, becoming number two in the world
|
The C$78.5-million deal aims to strengthen the company’s swine product portfolio
|
The $59.9-million deal aims to strengthen the company’s swine product portfolio
|
The reported deal would combine two of the world’s largest veterinary medicine companies
|
|
|
